ERBB2 and carcinoma: Moreover, DUSP1 is exclusively expressed in HER2+ carcinomas, which are relatively poor prognosis tumours but amenable to HER2-targeting therapies, and DUSP1 expression is associated with an increased risk of metastasis and shorter overall survival [17].